Sinovac Completes 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Trial

(RTTNews) - Sinovac Beijing, the principal operation subsidiary of Sinovac Biotech (SVA), has accomplished its 23-valent Pneumococcal Polysaccharide Vaccine Phase III clinical trial and filed the New Drug Application to CFDA on August, 3rd. The vaccine is used to prevent streptococcus pneumoniae (pneumococcus) infections, such as pneumonia and septicemia among adults aged 65 or older, adults with serious long-term health problems, smokers, and children older than two years with serious long-term health problems.

Only Merck Sharp&Dohme, Sanofi Pasteur, Chengdu Institute of Biological Products and Walvax Biotechnology have launched the 23-valent PPV so far.